English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

A clinical pharmacokinetic study was performed in 12 healthy women to evaluate systemic exposure to aluminum following topical application of a representative antiperspirant formulation under real‐life use conditions. A simple roll‐on formulation containing an extremely rare isotope of aluminum ( 26 Al) chlorohydrate ( ACH ) was prepared to commercial specifications. A  26 Al radio‐microtracer was used to distinguish dosed aluminum from natural background, using accelerated mass spectroscopy. The  26 Al citrate was administered intravenously (i.v.) to estimate fraction absorbed (F abs ) following topical delivery. In blood samples after i.v. administration,  26 Al was readily detected (mean area under the curve ( AUC ) = 1,273 ± 466 hours×fg/ mL ). Conversely, all blood samples following topical application were below the lower limit of quantitation ( LLOQ ; 0.12 fg/ mL ), except two samples (0.13 and 0.14 fg/ mL ); a maximal  AUC  was based on  LLOQ s. The aluminum was above the  LLOQ  (61 ag/ mL ) in 31% of urine samples. From the urinary excretion data, a conservative estimated range for dermal F abs  of 0.002–0.06% was calculated, with a mean estimate of 0.0094%.

Assessment of Dermal Absorption of Aluminum from a Representative Antiperspirant Formulation Using a 26 Al Microtracer Approach